Strive Asset Management has raised $750 million to pursue the strategy while Ramaswamy runs to be Ohio’s governor.

Hyderabad: Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III clinical trials. The vaccine maker, in a press release, said it has ...

Cash Position: Approximately $1 billion in cash equivalents and time deposits. Legend Biotech Corp (NASDAQ:LEGN) reported a 135% year-over-year increase in net trade sales for CARVYKTI ...

LONDON, May 14 (Reuters) - Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the ...

Legend Biotech USA Inc. CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI ® clinical ...

Health Net Connections LTD (HNC) providers of healthcare technology to hospitals, doctors surgeries and private clinics across the UK & Europe has appointed Faith Bose as its new UK sales director.

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., while barring companies from working ...

In this article, we will be taking a look at the 7 most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest ...

Certainty is the deadly enemy of tolerance,” he says. “Our faith is a living thing precisely because it walks hand in hand with doubt. If there was only certainty and no doubt, there would be ...

For Rituja Suraj Chavan, Managing Director of Valient Biotech Pvt Ltd, starting a company was never just about business—it was about making a difference. The company was founded with a dual ...

An analyst saw the response as an indication of faith in the Indian aviation story ... officer of KR Choksey Shares and Securities Pvt. Ltd. “From the fundamental valuation perspective, it ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...